share_log

HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $25 Price Target

HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $25 Price Target

HC Wainwright & Co.重申买入Entrada Therapeutics,维持25美元的目标股价
Benzinga ·  2023/08/02 06:20

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA) with a Buy and maintains $25 price target.

HC Wainwright&Co.分析师Raghuram Selvaraju重申Entrada治疗公司(纳斯达克:TRDA)的买入,并维持25美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发